Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.53 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838213 | 0.86 | ERN1 (0.55) | ERN1ALDH5A1ABATXDHS100A4 | |
| SCHEMBL28223814 | 0.85 | ERN1 (0.53) | ERN1ALDH5A1ABATXDHS100A4 | |
| SCHEMBL16838201 | 0.83 | ERN1 (0.51) | ERN1ALDH5A1ABATXDHGPR35 | |
| SCHEMBL16838215 | 0.83 | ERN1 (0.61) | ERN1ALDH5A1ABATXDHGPR35 | |
| SCHEMBL7421989 | 0.83 | ERN1 (0.40) | ERN1ALDH5A1ABATS100A4GPR35 | |
| SCHEMBL7421986 | 0.83 | S100A4 (0.43) | ERN1ALDH5A1ABATS100A4GPR35 | |
| SCHEMBL11868078 | 0.81 | ERN1 (0.46) | ERN1S100A4 | |
| SCHEMBL12362299 | 0.81 | ERN1 (0.50) | ERN1ALDH5A1ABATGPR35 | |
| SCHEMBL10907248 | 0.80 | EGFR (0.49) | ERN1 | |
| SCHEMBL29652066 | 0.79 | GPR35 (0.54) | ERN1ALDH5A1ABATS100A4GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013139931-A1 | COMPOSITION FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2013-09-26 | — | — | WO | claimed |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3904343-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | Zhejiang University (CN) | 2021-11-03 | — | — | EP | disclosed |
| CN-109516961-B | Aminoquinazolinone and aminoisoquinolinone derivatives and uses thereof | 浙江大学 | 2021-01-01 | — | — | CN | disclosed |
| CN-110003031-A | Amphiphilic molecule containing o-nitrobenzyl ester photodegradation group and synthetic method thereof | 大连理工大学 | 2019-07-12 | — | — | CN | disclosed |
| CN-109516961-A | Aminoquinazolinone and aminoisoquinoline ketone derivatives and its application | 浙江大学 | 2019-03-26 | — | — | CN | disclosed |
| CN-107652310-A | The cephem compounds of 2 substitutions | 葛兰素集团有限公司 | 2018-02-02 | — | — | CN | disclosed |
| CN-104884460-B | 2-substituted Cephem compounds | 葛兰素集团有限公司 | 2017-11-03 | — | — | CN | disclosed |
| US-9622988-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-04-18 | — | — | US | disclosed |
| US-8883857-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883857-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140329909-A1 | SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2014-11-06 | — | — | US | disclosed |
| US-20140329909-A1 | SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2014-11-06 | — | — | US | disclosed |
| US-20140163045-A1 | Small Molecule Xanthine Oxidase Inhibitors and Methods of Use | BAYLOR COLLEGE OF MEDICINE (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163045-A1 | Small Molecule Xanthine Oxidase Inhibitors and Methods of Use | BAYLOR COLLEGE OF MEDICINE (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013139931-A1 | COMPOSITION FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2013-09-26 | — | — | WO | disclosed |
| CN-101500419-A | Compounds useful for treating HIV | MILLENIA HOPE PHARMACEUTICALS (CA) | 2009-08-05 | — | — | CN | disclosed |
| US-5254726-A | Reacting aromatic nitroaldehydes having protected hydroxyl groups with labeled fluoride ion | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF ENERGY (US) | 1993-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | PIK3R5, PIK3CA, PIK3R1 | ERN1 3363/4885ALDH5A1 2595/4885ABAT 704/4885 |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | PIK3R5, PIK3CA, PIK3R1 | ERN1 3363/4885ALDH5A1 2595/4885ABAT 704/4885 |
| US-20140329909-A1 | SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | XDH, PNPO, AOX1 | ERN1 1482/4885ALDH5A1 238/4885ABAT 92/4885 |
| US-20140163045-A1 | Small Molecule Xanthine Oxidase Inhibitors and Methods of Use | XDH, PNPO, AOX1 | ERN1 1482/4885ALDH5A1 238/4885ABAT 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.